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 Macular degeneration is a heterogeneous group of disor-
ders. The most prevalent form, age-related macular degenera-
tion (AMD), is the leading cause of legal blindness in the eld-
erly in developed countries. Stargardt-like macular dystrophy
(STGD3, OMIM 600110) is an autosomal dominant form of
juvenile macular degeneration characterized by decreased vi-
sual acuity, macular atrophy, and extensive flecks [1,2]. The
disease shares some similarity with AMD including abnormal
accumulation of lipofuscin in the retinal pigment epithelium
(RPE) and degeneration of RPE and photoreceptors in the
macula. The disease-causing gene ELOVL4 encodes a protein
with sequence and structural similarities to the ELO family of
proteins. The ELO family of proteins is involved in the elon-
gation of long chain fatty acids and is characterized by mul-
tiple putative membrane-spanning domains, a histidine clus-
ter motif (HXXHH) involved in the enzymatic activity [3,4],
and an ER retention signal [5]. Human ELOVL4 protein has
314 amino acids with a putative dilysine motifs (KXKXX) at
the C-terminus thought to signal ER retention [6,7]. ELOVL4
and the ELO family members are thought to be a part of a
complex enzymatic system, which participate in the catalysis
of reduction reactions occurring during fatty acid elongation
[8,9]. Elovl4 proteins are strongly conserved throughout ver-
tebrate species [10,11].
Two ELOVL4 mutations causing juvenile macular degen-
eration have been identified thus far. The first mutation is a 5
base-pair (bp) deletion starting at position 790 of the open
reading frame (790_794delAACTT) [12]. This mutation re-
sults in a frame-shift and a premature stop codon. The result-
ant truncated protein contains seven aberrant amino acids and
deletes a 51 amino acid fragment, including the dilysine ER
retention signal at the C-terminus. The second mutation con-
tains two 1 bp deletions, 789delT and 794delT [13], which
produces a frame-shift nearly identical to the five base pair
deletion.
To characterize the potential function of ELOVL4 and
explore the functional consequence of the ELOVL4 trunca-
tion, we investigated subcellular locations of normal and 5 bp
deletion mutant ELOVL4 tagged with EGFP in tissue culture,
and studied the effects of mutant ELOVL4 on survival of trans-
fected cells. Here, we show that the wild type (wt) ELOVL4
protein, as expected, localized to the ER compartment in trans-
fected cells. In contrast, the truncated ELOVL4 was not re-
tained in the ER, was found in an aggregated form in the cyto-
plasm of transfected cells, and eventually caused apoptotic
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Conclusions: Unlike wtELOVL4/EGFP fusion protein, the mtELOVL4/EGFP fusion protein did not localize to the ER
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degeneration. Our study has provided an important in vitro model system for further assessment of ELOVL4 biochemical
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cell death. Together, our results suggest that mislocalization
of the mutant ELOVL4 protein, probably due to loss of the
putative ER retention motif, and subsequent induction of
apoptosis, may be the pathway leading to dominant Stargardt-
like macular degeneration in the human retina.
METHODS
Materials:  Media and reagents for cell culture and transfec-
tion were purchased from Gibco-BRL (Gibco, Grand Island,
NY). Anti-EGFP monoclonal antibody and poly-L-lysine were
purchased from Sigma (Sigma Chemical Co., St. Louis, MO).
Chamber slides were purchased from Nunc (Nalge Nunc In-
ternational, Rochester, NY).
Generation of expression constructs:  Wild type and 5 bp
deletion mutant ELOVL4 (wtELOVL4 and mt ELOVL4, re-
spectively) cDNAs were cloned separately into a pEGFPC1
vector (Clontech, Palo Alto, CA). This vector utilizes a CMV
promoter and expresses enhanced green florescent protein
(EGFP) following transfection into mammalian cells. PCR was
performed using one forward and two reverse primers 5'-CGG
GGT ACC GCG ATG GGG CTC CTG GAC TC-3', 5'-
CGGGATCCCG TTAATC TCC TTT TGC TTT TC-3', and
5'-CGGGATCCCG TTAGGC TCT TTG TAT GTC CGA-3'
(containing Kpn1 and BamH1 restriction sites) using wt and
mutant ELOVL4 cDNAs as templates. The resultant PCR prod-
ucts were digested with KpnI and BamHI, and cloned into the
KpnI and BamHI sites of a pEGFPC1 vector in frame at the C-
terminal end of EGFP (Figure 1) The recombinant plasmids
containing EGFP-ELOVL4 fusion constructs were verified by
direct DNA sequencing, amplified, and purified using a Qiagen
plasmid isolation kit (Qiagen Inc., Valencia, CA).
Transfection studies and image acquisition:  NIH3T3 and
HEK293 were used for all transfection studies. The cells were
maintained in Dulbecco’s Modified Eagles Medium (DMEM;
Gibco) supplemented with 10% fetal bovine serum (FBS;
Gibco), 100 i.u/ml of Penicillin, and 100 µg/ml of streptomy-
cin. The recombinant plasmids were transfected into the cell
lines using Lipofectamin Reagent 2000 (Gibco) according to
the manufacturer’s protocol. Cells were monitored for fluo-
rescence between 7-36 h post transfection using episcopic-
fluorescence microscopy.
NIH3T3 cells were seeded onto poly-L-lysine coated four
well chamber glass slides at a confluence of 30% and trans-
fected with recombinant plasmids containing wt or mt
ELOVL4. Cotransfection with organelle specific markers
pDsRed2ER, pDsRed2Mito, and pDsRed2peroxi (Clontech)
were performed with wt and mt ELOVL4 to determine the
subcellular localization of ELOVL4. Transfected cells were
incubated at 37  C for 24 h, washed twice with phosphate
buffer saline (PBS, pH  7.5), fixed in methanol:acetone (50:50,
V/V) for 5 min at -20 C, the chambers removed and glass
slides mounted with Vectashield mounting media (Vector labo-
ratories, Inc., Burlingame, CA) for microscopy. To assess pro-
gressive subcellular localization of wt and mt protein ELOVL4,
transfected cells were observed at different time intervals.
However, all data presented in this study was collected at ap-
proximately the same time point after transfection.
For Golgi colocalization study, transfected cells were
stained with BODIPY TR, a Golgi marker, per manufacturer’s
protocol (Molecular Probes, Inc., Eugene, OR)
Images of green fluorescence were collected using an
Olympus IX70 confocal laser scanning microscope using 488
nm excitation source and 505-550 nm band pass barrier filter.
Red fluorescence (DsRed2) markers for ER, mitochondria,
and peroxisomes were examined using 568 nm excitation light
from the He-Ne laser, a 575 nm dichroic mirror, and a 580-
625 nm filter. The cells were illuminated only during image
acquisition (3.7 s/frame for EGFP and DsRed2) and images
were collected (in a section of 0.5 µm and pin hole size of 2
µm) where images were compared for co-localization analy-
ses.
Electrophoresis and immunoblotting:  To analyze the ex-
pression of wt and mt ELOVL4, transfected cells were grown
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Figure 1. Recombinant constructs.  Schematic diagram of recombi-
nant constructs with position of amino acid depicted in numbers. A:
EGFP and wild type ELOVL4 (wtELOVL4) fusion protein. B: EGFP
and mutant ELOVL4 (mtELOVL4) fusion protein. Also labelled are
the cytomegalovirus promoter (pCMV) and the Simian virus (SV)
40 polyadenylation signal (pA).
Figure 2. Western blot analysis of fusion proteins.  Transfected
HEK293 cells were allowed to express EGFP/ELOVL4 fusion pro-
teins for 24 h, cells were harvested, followed by immunoblotting
using anti-GFP monoclonal antibody. Lane 1 is EGFP/wtELOVL4.
Lane 2 is EGFP/mtELOVL4. Lane 3 is EGFP alone as a vector con-
trol.
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for 24 h, harvested from the plates, and briefly washed with
PBS. Cells were lysed on ice for 20 min with a buffer contain-
ing 1% Triton X-100, 0.01% SDS, 0.05 M Tris-HCl, and 0.001
M EDTA (pH 7.5). The cell lysates were centrifuged at 4000
rpm for 5 min and supernatants used for electrophoresis.
SDS polyacrylamide gel electrophoresis (SDS-PAGE)
was performed according to the method of Laemmli [14]. Ten
µl of sample (about 7 µg protein) was loaded onto a 9% poly-
acrylamide gel and electrophoresed at 110 V for 1 h. The re-
solved proteins were transferred to a PVDF membrane
(Millipore, Billerica, MA), and blocked for 2 h at room tem-
perature with 5% skim milk in Tris buffered saline containing
0.05% Tween 20 (TTBS). The membrane was incubated for 2
h with monoclonal antiGFP antibody diluted 1:2000 in 5%
milk containing TTBS, and then probed with peroxidase-con-
jugated antimouse antibody (1:4000 dilution in TTBS,
Amersham Biosciences, NJ) for 1 h and developed with an
ECL (Amersham Bioscience) detection kit according to the
manufacturers’ protocol.
Apoptosis assay in transfected cultured cells:  An in situ
apoptotic cell death detection kit TMR red (Roche Applied
Science, Indianapolis, IN) based on a TUNEL assay, was used
to detect apoptotic cells in cultures expressing wt or mt
ELOVL4. The TUNEL assay was performed on transfected
cells after 20 h incubation, as per manufacturer’s protocol.
Apoptotic cells were visualized using episcopic-fluorescence
microscopy at 20x and 40x magnification. Transfection posi-
tive cells were scored by green fluorescence and tunnel posi-
tive cells scored by red nuclear staining using 20x magnifica-
tion. Data were collected from 3 separate sets of transfection
©2004 Molecular VisionMolecular Vision 2004; 10:248-53 <http://www.molvis.org/molvis/v10/a31>
Figure 3. Intracellular
localication of EGFP/wt
ELOVL4 fusion protein.  Lo-
calization of wtELOVL4-
EGFP fusion protein with dif-
ferent organelle specific mark-
ers in NIH3T3 cells. The cells
were imaged using confocal
microscopy 24 h following co-
transfection. Green images
represent the expression of
ELOVL4 and red images rep-
resent different organelles.
Merged color image: superim-
posed image of green and red.
A: Co-transfected cell with
EGFP/wtELOVL4 and
pDsRed2-ER (specific for En-
doplasmic Reticulum). B: Co-
transfected cell with EGFP/
wtELOVL4 and pDsRed2-
Peroxi (specific for peroxi-
somes). C: co-transfected cell
with EGFP/wtELOVL4 and
PDsRed2-Mito (specific for
mitochondria). D: Cells were
transfected with EGFP/




experiments (duplicate wells). Results are presented as per-
cent apoptotic cells per 550 EGFP-ELOVL4 fusion protein
positive cells.
RESULTS
Characterization of EGFP-ELOVL4 fusion proteins:  In
this study we expressed wt and mt ELOVL4 as EGFP fusion
proteins to facilitate direct visualization of subcellular local-
ization (Figure 1). Western blot analysis confirmed the syn-
thesis of EGFP-ELOVL4 fusion proteins; single bands were
visualized for each construct at approximately 61 kDa for wt
ELOVL4 and approximately 56 kDa for the EGFP-ELOVL4
truncated mutant (Figure 2). Culture medium was also exam-
ined by western blot analyses; no detectable protein was found
(data not shown).
Subcellular localization of ELOVL4:  Episcopic-fluores-
cence and confocal microscopy were used to determine the
subcellular localization of wt and mt ELOVL4 in transfected
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ing were performed in
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cells Wild type ELOVL4 localized preferentially to the ER
compartment (Figure 3A), but showed no evidence of co-lo-
calization in peroxisomes when cotransfected with DsRed
peroxisomes (Peroxi; Figure 3B), nor mitochondria (Figure
3C) when cotransfected with DsRed mitochondria (Mito)
markers. There was also very little Golgi co-localization of wt
ELOVL4 when transfected cells were co-stained with BODIPY
TR, a Golgi marker (Figure 3D). In contrast, mtELOVL4
showed markedly different subcellular localization pattern in
the transfected cells. It did not localize to the ER (Figure 4A),
peroxisomes (Figure 4B), mitochondria (Figure 4C), or Golgi
(Figure 4D). Instead, the pattern of its subcellular distribution
is consistent with an aggregated form in the cytoplasm. As a
control, EGFP when expressed alone, localized to the cyto-
plasm as reported previously (data not shown) [15].
Cytotoxicity of mtELOVL4/EGFP fusion protein:  We
found that a significant number of transfected cells express-
ing mutant (mt) ELOVL4/EGFP fusion protein died in cul-
ture. This observation prompted us to investigate whether the
mutant induces cells to undergo programmed cell death. An in
situ cell death assay (TUNEL) for apoptosis was performed.
Transfected cell populations expressing mtELOVL4 showed
a marked increase in apoptotic cell death as evidenced by posi-
tive TUNEL staining in comparison to cells expressing
wtELOVL4. Specifically, a nine-fold (about 23% of 560 total
number of cells) induction in apoptotic cell death was observed
when the cells were transfected with mtELOVL4-EGFP fu-
sion plasmid (Figure 5). In contrast, cells transfected with
wtELOVL4-EGFP fusion plasmid showed a level of apoptosis
comparable to that of EGFP expression vector (Figure 5).
Therefore, overexpression of wtELOVL4-EGFP fusion pro-
tein does not induce apoptosis.
DISCUSSION
 Stargardt-like macular dystrophy (STGD3) is an autosomal
dominant form of juvenile macular degeneration and is char-
acterized by bilateral atrophic changes in the macula, degen-
eration of the underlying RPE, and the presence of prominent
flecks in the posterior pole[1,12,16]. The disease-causing gene
ELOVL4 encodes a protein with similarities to a family of
proteins involved in the elongation of long chain fatty acids.
Since normal ELOVL4 functions in photoreceptors, and the
mechanism whereby mutations in ELOVL4 lead to macular
degeneration are unknown, we investigated subcellular distri-
bution of normal and mutant ELOVL4 and effects of mutant
protein expression on cell viability.
Given the sequence similarity of ELOVL4 to a family of
proteins functioning in elongation of long chain fatty acids,
including dilysine ER retention signal, one would expect that
normal ELOVL4 localizes to ER, the site of protein synthesis
and fatty acid elongation. Indeed, our results of NIH3T3 cell
transfection studies indicated ER localization for normal
ELOVL4. To avoid bias of NIH3T3 cell lines, we also found
ER localization of ELOVL4-EGFP fusion protein in two other
cell lines, HEK293 and COS7 (data not shown). Although there
is a small possibility that ER localization of EGFP-ELOVL4
is an artifact of the fusion protein, we believe that the ER lo-
calization represents authentic location of ELOVL4 native
protein for the following reasons: First, our control transfec-
tion experiments showed that EGFP when expressed alone
localized to the cytoplasm (data not shown); second, the EGFP/
mtELOVL4 lacking 51 C-terminal amino acids including a
dilysine ER retention signal, did not localize to the ER. Fur-
ther experiments using ELOVL4-specific antibodies will verify
the above findings.
Unlike wtELOVL4-EGFP fusion protein, the mutant does
not localize to the ER but rather appears to be sequestered
elsewhere, showing dense fluorescent-positive aggregates. Uti-
lizing the available organelle markers on hand, we found that
the mtELOVL4-EGFP fusion protein does not reside within
peroxisomes, Golgi, or mitochondria but rather some alterna-
tive unidentified compartment. Based on our microscopic stud-
ies, it is possible that the truncation of ELOVL4 renders the
polypeptide prone to form high molecular weight oligomeric
species in the cytoplasm of transfected cells, accumulating in
an aggregated form. Future studies with additional cell mark-
ers and/or electron microscopy will elucidate more precisely
the subcompartmental localization of the mutant protein.
We demonstrated that mislocalized mtELOVL4-EGFP
fusion protein induces apoptotic cell death in HEK293 cells.
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Figure 5. Apoptosis induced by fusion protein expression.  TUNEL
assay of transfected HEK293 cells expressing EGFP/wtELOVL4
(WT) or EGFP/mtELOVL4 (MT) fusion proteins. The TUNEL as-
say of vector control (VC) is co-plotted. Assays were performed af-
ter 20 h of transfection. After a TUNEL reaction, cells were observed
using episcopic-fluorescence microscope. The green channel was used
to detect fusion protein expression and red channel was used to de-
tect apoptotic nuclear staining. Results were plotted as percent
apoptotic cells per equivalent number of transfected cells.
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We also observied similar findings in NIH3T3 and COS7 cell
lines (data not shown). There is a nine-fold increase in TUNEL
reactivity in transfected HEK293 cell populations expressing
mtELOVL4-EGFP fusion protein, relative to that expressing
wtELOVL4-EGFP fusion protein. The above results support
a model that dominant negative effects rather then haploid
insufficiency of ELOVL4 is a basis for retinal photoreceptor
degeneration in Stargardt-like macular dystrophy. Apoptosis
induced by mutant ELOVL4 could be a general mechanism
rather than a photoreceptor-specific one, since apoptosis was
observed in non-photoreceptor cells.
Although the primary sequence of ELOVL4 shows strong
sequence similarity to a family of conserved proteins involved
in elongation of long chain fatty acids, its putative enzymatic
function has not been established. Our study has provided an
important in vitro model system for further assessment of
ELOVL4 biochemical functions.
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